Skip to main content

Market Overview

Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced In

Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced In

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT), which is considered the frontrunner in the race for a non-alcoholic steatohepatitis, or NASH, drug, are fairly valued at current levels, according to an analyst at Citigroup.

The Analyst

Joel Beatty downgraded Intercept from Buy to Neutral and increased the price target from $85 to $140.

The Thesis

Intercept shares are now about 95% higher since September vis-à-vis the 11% gain for the S&P 500 Index during the same timeframe, Beatty said in a Thursday note. The analyst believes the NASH launch is appropriately priced in.

The price target hike, according to Beatty, reflected incremental conviction in the NASH opportunity and the discontinuation of rival CymaBay Therapeutics Inc's (NASDAQ: CBAY) Seladelpar in primary biliary cholangitis, or PBC, an autoimmune liver disease.

The analyst had viewed Seladelpar as a real threat to the PBC market share.

The next major catalyst for Intercept is the Adcom meeting scheduled for April 22, Beatty said. The analyst assigns a 90% probability for the approval coming through.

Upside on a potential approval could be a modest 10-15%, although downside if rejected could be a steeper 80%.

"….many investors owning into the approval may not want to own into a relatively uncertain NASH launch," Beatty wrote in the note.

Intercept shares were slipping 5% to $117.49.

Related Links:

Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa

Latest Ratings for ICPT

Mar 2021HC Wainwright & Co.UpgradesSellNeutral
Mar 2021NeedhamMaintainsBuy
Mar 2021WedbushMaintainsOutperform

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings


Related Articles (ICPT)

View Comments and Join the Discussion!

Posted-In: Citigroup Joel BeattyAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

Latest Ratings

SCYXAegis CapitalMaintains40.0
ARGOBoenning & ScattergoodDowngrades
TLSAZacks Investment ResearchInitiates Coverage On7.5
TOTJP MorganUpgrades
WSOMorgan StanleyMaintains244.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at